Programma Scientifico
FEBRUARY 25th 2021
| 15.30-15.45 | Welcome and introduction A. Antinori, A. d’Arminio Monforte |
| Data updates from the ICONA Cohort | |
|
SESSION 1: HIV AND SARS-COV-2 Moderators: M. Galli, G. Ippolito |
|
| 15.45-16.00 | Lecture Are PLWH at higher risk of worse COVID-19 prognosis compared with HIV neg? A. Antinori |
| 16.00-16.15 | Impact of lockdown on HIV care in Italy C. Pinnetti |
| 16.15-16.30 | Study proposals on HIV SARS-CoV-2 coinfection from the ICONA Cohort F. Ceccherini-Silberstein, G. Marchetti |
| 16.30-16.45 | Discussion conducted by Moderators |
|
SESSION 2: IMMUNO VIROLOGICAL DATA Moderators: M. Andreoni, A. Gori |
|
| 16.45-17.00 | Lecture HIV virological issues in 2020 C.F. Perno |
| 17.00-17.10 | Impact of multi-drug resistance on mortality: a multi-cohort Italian study A. Cozzi-Lepri |
| 17.10-17.20 | Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data C. Alteri |
| 17.20-17.35 | Discussion conducted by Moderators |
|
SESSION 3: QUALITY OF LIFE IN PLWH Moderators: R. Cauda, R. Iardino, F. von Schloesser |
|
| 17.35-17.50 | Lecture Patient reported outcomes to value innovation in HIV treatment O. Ciani |
| Round table on significance of PROs in HIV management | |
| 17.50-18.05 | The role of innovative therapies A. Castagna |
| 18.05-18.20 | PROs measurements: implications and consequences F. Maggiolo |
| 18.20-18.35 | Patients perspective on PROs M. Errico |
| 18.35-18.50 | ICONA e-QoL Project A. Cingolani |
| 18.50-19.05 | Discussion conducted by Moderators |
| 19.05-19.15 | Take-home messages from first working sessions A. Antinori, A. d’Arminio Monforte |
FEBRUARY 26th 2021
| 15.00-15.30 | Presentation of the ICONA App |
|
SESSION 4: CLINICAL ISSUES Moderators: F. Castelli, M. Puoti |
|
| 15.30-15.45 | Lecture Weight gain: the state of art G. Guaraldi |
| 15.45-15.55 | Causes and incidence of hospitalization in patients enrolled in the ICONA Cohort S. Nozza |
| 15.55-16.05 | Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH) V. Mazzotta |
| 16.05-16.15 | Risk of weight gain (WG) according to type of switching strategy in a large Cohort of HIV-infected individuals with stable suppressed HIV-RNA S. Cicalini |
| 16.15-16.30 | Discussion conducted by Moderators |
|
SESSION 5: ANTIRETROVIRAL THERAPY Moderators: G. Di Perri, C. Mussini |
|
| 16.30-16.40 | Adults with multidrug resistant HIV-1 infection for whom it is not possible to construct a suppressive ARV regimen due to resistance, intolerance or safety considerations in the Italian ICONA Cohort S. Lo Caputo |
| 16.40-16.50 | Reasons for choosing a 2DR or a TAF-based 3DR as ART switch strategy in second line therapies for virologically suppressed PLWH in Italy A. Vergori |
| 16.50-17.05 | Discussion conducted by Moderators |
|
SESSION 6: EPIDEMIOLOGY and SOCIAL ISSUES Moderators: A. Lazzarin, G. Rezza, A. Perziano |
|
| 17.05-17.20 | Lecture Are PLWH at higher risk of SARS-CoV-2 infection compared with HIV neg? E. Girardi |
| 17.20-17.30 | Post-migration HIV infection in the foreign-born population enrolled in the ICONA Cohort A. Saracino |
| 17.30-17.40 | U=U status in people living with HIV after switching to dual antiretroviral therapy: results from the ICONA Cohort G. Madeddu |
| 17.40-17.50 | Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA) in Italy and correlation with the level of confidence in reference physicians A. Cingolani |
| 17.50-18.05 | Discussion conducted by Moderators |
| 18.05-18.15 | Final considerations A. Antinori, A. d’Arminio Monforte |